Oncocyte announced plans to file a Form 12b-25 with the U.S. SEC regarding its Annual Report on Form 10-K and reports preliminary financial results for the full year ended December 31, 2022. The company is completing its final review of the information required to be presented for the relevant period. The Form 12b-25 provides the company with an additional 15 calendar days to complete its assessment and allows its independent registered public accounting firm extra time to complete its audit of the company’s financial statements before filing its Form 10-K reports. The company currently anticipates filing the 2022 Form 10-K as soon as practicable and expects that, in compliance with Rule 12b-25, it will be filed no later than April 17. "The Company continues to work diligently to submit the filing. Turning to our recent performance, we have committed to a strategic shift from a service lab model to a product-driven revenue model with low-cost infrastructure and scalable high-margin distributable content," said Joshua Riggs, CEO. "With a reduced cash burn, we believe this puts us in a better position to support the future of our core products and rapidly deliver on our major milestones ahead. We are confident that a kitted product approach puts our unique technology in the hands of researchers at every level, from pharma to academia, encouraging research on the role of the tumor microenvironment in oncology and transplant graft health and viability."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on OCX:
- OncoCyte Corp (OCX) Q4 Earnings Cheat Sheet
- Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K
- Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call
- Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results
- OncoCyte appoints Riggs as President, CEO